Nextage Therapeutics Current Valuation vs. Cash And Equivalents
| NXTG Stock | ILA 77.60 2.30 3.05% |
For Nextage Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nextage Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nextage Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nextage Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nextage Therapeutics over time as well as its relative position and ranking within its peers.
Nextage |
Nextage Therapeutics Cash And Equivalents vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nextage Therapeutics's current stock value. Our valuation model uses many indicators to compare Nextage Therapeutics value to that of its competitors to determine the firm's financial worth. Nextage Therapeutics is rated top company in current valuation category among its peers. It also is considered to be number one stock in cash and equivalents category among its peers creating about 0.03 of Cash And Equivalents per Current Valuation. The ratio of Current Valuation to Cash And Equivalents for Nextage Therapeutics is roughly 37.51 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nextage Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nextage Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nextage Current Valuation vs. Competition
Nextage Therapeutics is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is now estimated at about 14.64 Billion. Nextage Therapeutics adds roughly 13.43 Million in current valuation claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Nextage Cash And Equivalents vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Nextage Therapeutics |
| = | 13.43 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Nextage Therapeutics |
| = | 358 K |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Nextage Cash And Equivalents Comparison
Nextage Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Nextage Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nextage Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nextage Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Nextage Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Nextage Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. The company was formerly known as Micromedic Technologies Ltd and changed its name to Nextage Therapeutics Ltd in August 2020. NEXTAGE THERAPEUTI operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Nextage Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nextage Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nextage Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nextage Therapeutics' important profitability drivers and their relationship over time.
Use Nextage Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nextage Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nextage Therapeutics will appreciate offsetting losses from the drop in the long position's value.Nextage Therapeutics Pair Trading
Nextage Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Nextage Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nextage Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nextage Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nextage Therapeutics to buy it.
The correlation of Nextage Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nextage Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nextage Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nextage Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Nextage Therapeutics position
In addition to having Nextage Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Pharmaceutical Products Thematic Idea Now
Pharmaceutical Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nextage Stock
To fully project Nextage Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nextage Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nextage Therapeutics' income statement, its balance sheet, and the statement of cash flows.